MeMed Diagnostics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, MeMed Diagnostics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
MeMed Diagnostics: 4 sponsored US clinical trials, 1 recruiting.
MeMed Diagnostics sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Lower Respiratory Tract Infection, with 1 trials.
Upper-quartile sponsor footprint
MeMed Diagnostics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
NCT05762302
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
NCT06665542
Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)
NCT05439551
Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)
NCT04690569
Therapeutic Areas
What is open in the MeMed Diagnostics pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lower Respiratory Tract Infection (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MeMed Diagnostics: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
MeMed Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this MeMed Diagnostics page
4 registered trials is a research-attention snapshot, not an endorsement of MeMed Diagnostics or any single study.
- 1 of MeMed Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lower Respiratory Tract Infection is the condition MeMed Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lower Respiratory Tract Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MeMed Diagnostics pipeline card: 4 registered trials from official public datasets.Report a data error.